Table 1.
In Vitro Sensitivity of TNBC Lines to Chemotherapeutic Drugs.
| Drug | Mode of Action | IC50 (nM) | Fold Change in IC50 | |
| MDA-MB-231 | HCC1806* | MDA-MB-231 vs HCC1806 | ||
| Nab-paclitaxel | Microtubule stabilizer | 10 | 0.78 | 12.82 |
| Paclitaxel | Microtubule stabilizer | 12 | 0.78 | 15.38 |
| Perifosine | MAPK inhibitor | 3,500 | 600 | 5.83 |
| Doxorubicin | DNA cross linker | 625 | 5,000 | 0.12 |
| Cisplatin | DNA intercalator | 10,000 | 2,500 | 4.00 |
| Erlotinib | EGFR inhibitor | 150,000 | 75,000 | 2.00 |
| Bevacizumab | Anti-VEGF-A antibody | No effect | No effect | N/A† |
MAPK indicates mitogen-activated protein kinase.
*
HCC1806 and the line derivatives HCC1806-RR isolates showed identical sensitivity to all tested drugs.
†
N/A denotes not applicable.